Humanized anti-IL-17A antibody has been evaluated in the setting of non-infectious autoimmune uveitis showing clinical benefits when delivered intravenously at 10–30 mg/kg biweekly for two months [47]. This evidence concerns the gene IL17A and autoimmune uveitis.